Agglomerative epigenetic aberrations are a common event in human breast cancer

Cancer Research

Volumn 68, Issue 20, 2008, Pages 8616-8625

  Novak, Petr ^a,d   Jensen, Taylor ^a,b   Oshiro, Marc M ^a   Watts, George S ^a   Kim, Christina J ^a,c   Futscher, Bernard W ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d INSTITUTE OF PLANT MOLECULAR BIOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN;

ARTICLE; BREAST CANCER; CANCER TISSUE; CHROMOSOME 5; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FEMALE; GENE CLUSTER; GENE DUPLICATION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION INITIATION SITE;

BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MULTIGENE FAMILY; REPRESSOR PROTEINS;

EID: 54249097887     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1419     Document Type: Article

References (50)

1. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92.
2. Narayan A, Ji W, Zhang XY, et al. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer 1998;77:833-8.
3. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301:89-92.
4. Jackson K, Yu MC, Arakawa K, et al. DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther 2004;3:1225-31.
5. Vertino PM, Spillare EA, Harris CC, Baylin SB. Altered chromosomal methylation patterns accompany oncogene-induced transformation of human bronchial epithelial cells. Cancer Res 1993;53:1684-9.
6. Baylin SB. Abnormal regional hypermethylation in cancer cells. AIDS Res Hum Retroviruses 1992;8:811-20.
7. Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 1989;83:155-8.
8. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000;24:132-8.
9. Novak P, Jensen T, Oshiro MM, et al. Epigenetic inactivation of the HOXA gene cluster in breast cancer. Cancer Res 2006;66:10664-70.
10. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 2006;38:540-9.
11. Hitchins MP, Lin VA, Buckle A, et al. Epigenetic inactivation of a cluster of genes flanking MLH1 in microsatellite-unstable colorectal cancer. Cancer Res 2007;67:9107-16.
12. Stransky N, Vallot C, Reyal F, et al. Regional copy number-independent deregulation of transcription in cancer. Nat Genet 2006;38:1386-96.
13. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994;22:2990-7.
14. Coolen MW, Statham AL, Gardiner-Garden M, Clark SJ. Genomic profiling of CpG methylation and allelic specificity using quantitative high-throughput mass spectrometry: critical evaluation and improvements. Nucleic Acids Res 2007;35:e119.
15. Weber M, Davies JJ, Wittig D, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005;37:853-62.
16. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
17. Chen Z, McGee M, Liu Q, Scheuermann RH. A distribution free summarization method for Affymetrix GeneChip(R) arrays. Bioinformatics 2007;23:321-7.
18. Kent WJ. BLAT-the BLAST-like alignment tool. Genome Res 2002;12:656-64.
19. Jensen TJ, Novak P, Eblin KE, Gandolfi AJ, Futscher BW. Epigenetic Remodeling During Arsenical-Induced Malignant Transformation. Carcinogenesis 2008;29:1500-8.
20. Nouzova M, Holtan N, Oshiro MM, et al. Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays. J Pharmacol Exp Ther 2004;311:968-81.
21. Li J, Yang Y, Fujie T, et al. Expression of BAGE, GAGE, and MAGE genes in human gastric carcinoma. Clin Cancer Res 1996;2:1619-25.
22. De Backer O, Arden KC, Boretti M, et al. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res 1999;59:3157-65.
23. Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J. p53 mutations in breast cancer. Cancer Res 1992;52:5291-8.
24. Wu Q, Maniatis T. A striking organization of a large family of human neural cadherin-like cell adhesion genes. Cell 1999;97:779-90.
25. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001;61:3105-9.
26. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant dna methylation in all common human cancers. Cancer Res 1995;55:4525-30.
27. Huang TH-M, Laux DE, Hamlin BC, Tran P, Tran H, Lubahn DB. Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique. Cancer Res 1997;57:1030-4.
28. Miyamoto K, Fukutomi T, Akashi-Tanaka S, et al. Identification of 20 genes aberrantly methylated in human breast cancers. Int J Cancer 2005;116:407-14.
29. Oshiro MM, Kim CJ, Wozniak RJ, et al. Epigenetic silencing of DSC3 is a common event in human breast cancer. Breast Cancer Res 2005;7:R669-80.
30. Raman V, Martensen SA, Reisman D, et al. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 2000;405:974-8.
31. Rauch TA, Zhong X, Wu X, et al. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci U S A 2008;105:252-7.
32. Ehrich M, Nelson MR, Stanssens P, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A 2005;102:15785-90.
33. Xie X, Mikkelsen TS, Gnirke A, Lindblad-Toh K, Kellis M, Lander ES. Systematic discovery of regulatory motifs in conserved regions of the human genome, including thousands of CTCF insulator sites. Proc Natl Acad Sci U S A 2007;104:7145-50.
34. Kim TH, AbdullaevZK, Smith AD, et al. Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome. Cell 2007;128:1231-45.
35. Filippova GN, Lindblom A, Meincke LJ, et al. A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers. Genes Chromosomes Cancer 1998;22:26-36.
36. Filippova GN, Qi CF, Ulmer JE, et al. Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity. Cancer Res 2002;62:48-52.
37. Butcher DT, Rodenhiser DI. Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours. Eur J Cancer 2007;43:210-9.
38. Filippova GN, Cheng MK, Moore JM, et al. Boundaries between chromosomal domains of X inactivation and escape bind CTCF and lack CpG methylation during early development. Dev Cell 2005;8:31-42.
39. Butcher DT, Mancini-DiNardo DN, Archer TK, Rodenhiser DI. DNA binding sites for putative methylation boundaries in the unmethylated region of the BRCA1 promoter. Int J Cancer 2004;111:669-78.
40. De La Rosa-Velazquez IA, Rincon-Arano H, Benitez-Bribiesca L, Recillas-Targa F. Epigenetic regulation of the human retinoblastoma tumor suppressor gene promoter by CTCF. Cancer Res 2007;67:2577-85.
41. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 2000;405:486-9.
42. Bell AC, Felsenfeld G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 2000;405:482-5.
43. Whitman SP, Liu S, Vukosavljevic T, et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood 2005;106:345-52.
44. Guenther MG, Jenner RG, Chevalier B, et al. Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci U S A 2005;102:8603-8.
45. Yu BD, Hess JL, Horning SE, Brown GAJ, Korsmeyer SJ. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 1995;378:505-8.
46. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003;100:11606-11.
47. Decensi A, Serrano D, Bonanni B, Cazzaniga M, Guerrieri-Gonzaga A. Breast cancer prevention trials using retinoids. J Mammary Gland Biol Neoplasia 2003;8:19-30.
48. Langston AW, Gudas LJ. Retinoic acid and homeobox gene regulation. Curr Opin Genet Dev1 994;4:550-5.
49. Song JZ, Stirzaker C, Harrison J, Melki JR, Clark SJ. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 2002;21:1048-61.
50. Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM. DNA motifs associated with aberrant CpG island methylation. Genomics 2006;87:572-9.